Urinary markers for urothelial cancer

BJU International

Volumn 92, Issue 6, 2003, Pages 531-533

  Sozen S ^a   Eskicorabci, S ^a   Ozen H ^a  

^a NONE

Author keywords

Bladder cancer; Detection; Screening; Surveillance

Indexed keywords

FIBRINOGEN DEGRADATION PRODUCT; HERMES ANTIGEN; HYALURONIC ACID; HYALURONIDASE; TUMOR MARKER;

BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CYSTOSCOPY; CYTOLOGY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE COST; HEALTH SURVEY; HUMAN; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; INTERMETHOD COMPARISON; LATEX AGGLUTINATION TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SHORT SURVEY; URINALYSIS; URINE CYTOLOGY; UROGENITAL TRACT CANCER;

CARCINOMA, TRANSITIONAL CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MASS SCREENING; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0142124063     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04427.x     Document Type: Short Survey

References (20)

1. Black RJ, Bray F, Ferloy J et al. Cancer incidence and mortality in the European Union Cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075-107
2. Landis SH, Murray T, Bolden S et al. Cancer Statistics, 1998. Ca Cancer J Clin 1998; 48: 6-9
3. Millan-Rodriguez F, Chechile-Tonioto G, Salvador-Bayarri J et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000; 164: 680-4
4. Herr HW, Intravesical BCG. Current results, natural history and implications for urothelial cancer prevention. J Cell Biochem Suppl 1992; 161: 112-9
5. Weiner HG, Vooijs GP, van't Hof-Grootenboer B. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol 1993; 37: 163-9
6. Malik SN, Murphy WM. Monitoring patients for bladder neoplasms. What can be expected of urinary cytology consultations in clinical practise. Urology 1999; 54: 62-6
7. Haukaas S, Daehlin L, Maartmann-Moe H, Ulvik NM. The long term outcome in patients with superficial transitional cell carcinoma of the bladder: a single-institutional experience. BJU Int 1999; 83: 957-63
8. Öge Ö, Erdem E, Atsü N ét al. Proposal changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor. Eur Urol 2000; 37: 271-4
9. Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol 2002; 167: 75-9
10. Sanchez-Carbayo M, Urrutia M, Gonzales de Buitrago JM et al. Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma. Cancer 2001; 92: 2820-8
11. Blumenstein BA, Ellis WJ, Ishak LM. The relationship between serial measurements of the level of a bladder tumor associated antigen and the potential for recurrence. J Urol 1999; 161: 57-61
12. Sharma S, Zippe C, Pandrangi L et al. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999; 162: 53-7
13. Atsü N, Ekici S, Öge Ö et al. False positive results of the NMP22 test due to hematuria. J Urol 2002; 167: 555-8
14. Öge Ö, Kozaci D, Gemalmaz H. The BTAstat test is nonspecific for hematuria: An experimental hematuria model. J Urol 2002; 167: 1318-20
15. Sözen S, Biri H, Sinik Z et al. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder. Eur Urol 1999; 36: 225-9
16. Lokeshwar VB, Schroeder GL, Selzer MG et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-stat tests. Cancer 2002; 95: 61-72
17. van Rhijn BW, Lurkin I, Kirkels WJ et al. Microsatellite analysis-DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer 2001; 92: 768-75
18. Lokeshwar VB, Soloway MS. Current bladder tumor tests: Does their projected utility fulfill clinical necessity? J Urol 2001; 165: 1067-77
19. Saad A, Hanbury DC, McNicholas TA et al. The early detection and diagnosis of bladder cancer: a critical review of the options. Eur Urol 2000; 39: 619-33
20. Öge Ö, Atsü N, Şahin A et al. Comparison of BTA stat and NMP22 tests in the detection of bladder cancer. Scand J Urol Nephrol 2000; 34: 349-51